Sean Salmon Named EVP & President Cardiovascular Portfolio; Continues as EVP & President Diabetes Operating Unit
News provided by
Share this article
Share this article
DUBLIN, Dec. 14, 2020 /PRNewswire/ Medtronic plc (NYSE:MDT) announced today that Sean Salmon, Executive Vice President and President, Diabetes Operating Unit has been named Executive Vice President and President, Cardiovascular Portfolio effective January 1. Salmon will also continue to lead the Diabetes Operating Unit and continue to serve on the company s Executive Committee. He succeeds Mike Coyle, who will leave Medtronic effective December 31 to accept a CEO role of a publicly traded company. We owe Mike a debt of gratitude for his significant contributions to Medtronic, said Geoff Martha, Medtronic Chairman and Chief Executive Officer. He s played a vital role in our Cardiovascular portfolio, including overseeing the development and launches of numerous disruptive and life-saving technologies. On behal
The end of the year affords us the opportunity to remember those we lost.
Happy holidays! With this issue we close out the year by presenting to you our Person of the Year the individual who, more than anyone else, has had a recent and profound effect on Minnesota’s reputation, economy and society.
This year’s choice leads one of the two largest medical device and technology firms in the world, which also happens to be one of Minnesota’s largest employers and philanthropic contributors. He has steered his business away from stagnating sales into higher growth territories organically and through acquisitions, including the largest med-tech merger in history. And he has led it through controversies. You can read more about Medtronic Chairman and CEO Omar Ishrak in the article 2015 Person Of The Year: Omar Ishrak.